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Pedal-Cycle Injuries Among Children Aged <6 YearsWisconsin, 2002-2004
Measures to improve pedal-cycle* safety and increase helmet use often target school-age children rather than younger children (1) , even though preschool children wearing helmets have fewer injuries (2) and are more likely to wear helmets in the future (3), compared with children who do not wear helmets. Children aged <6 years also use pedal cycles; whether they are passengers on a parent's bicycle, riding a tricycle or pedal car, or learning to ride a bicycle, these young cyclists often sustain injuries (1) . To provide guidance for intervention strategies targeted to young children in Wisconsin, CDC and the Wisconsin Division of Public Health analyzed data collected from January 1, 2002 through December 31, 2004, from all nonfederal emergency departments (EDs) and hospitals in Wisconsin regarding pedal-cycle injuries among children aged <6 years. This report describes the results of that analysis, which indicated that, during 2002-2004, a total of 2,046 ED visits by Wisconsin residents aged <6 years for pedal-cycle injuries occurred; for 1,305 (63.8%) of these visits, the primary diagnosis was a head or neck injury. These findings underscore the need for interventions designed to reduce head and neck injuries in the youngest users of pedal cycles.
The Wisconsin Bureau of Health Information and Policy maintains data from ED visits and hospital discharges through a statewide mandatory reporting system for nonfederal hospitals. An injury event was defined as a 2002-2004 ED visit or hospitalization for a Wisconsin resident aged <6 years with an International Classification of Diseases, Ninth Revision, Clinical Modification code from 800 to 959 indicating injury as one of the diagnoses for the encounter and an E-code indicating an injury sustained by a rider or passenger on a pedal cycle † (4) . In addition, the Wisconsin Vital Records Office collects mortality information for the state; pedal-cycle deaths were defined as reports with International Classification of Diseases and Related Health Problems, Tenth Revision codes V10-V19 as the underlying or contributing cause of death. U.S. Census Bureau population estimates from 2002 were used to calculate incidence rates (5) . The Barell Injury Diagnosis Matrix was used to classify the primary diagnosis by body location and nature of the injury (6) . Secondary diagnoses were excluded for the purpose of this analysis. For comparison, the number and proportion of ED visits for head and neck injuries for Wisconsin children aged 6-18 years were calculated using the same methodology. In addition, for two areas, Port Washington (population: 10,518) and Milwaukee County (population: 934,352), the number of pedal-cyclerelated ED visits and the proportion of head and neck injuries in residents aged <6 years were examined separately to determine whether a mandatory helmet law in Port In Wisconsin, most pedal-cycle injury ED visits for children aged <6 years did not involve motor vehicles. These findings are consistent with a study using 1993-1997 data from the National Hospital Ambulatory Medical Care Survey (NHAMCS) (1) . In addition, the NHAMCS study indicated that only 24% of bicycle-related injuries among children aged <4 years occurred in a street (1) .
The findings in this report are subject to at least six limitations. First, ED data likely are underestimates of the total number of injuries and might be overestimates of the proportion of head and neck injuries. Parents might not seek medical attention for minor injuries, or they might take the child to their regular doctor. Second, the ED database does not contain information on whether the child wore a helmet or where the incident occurred, preventing analysis of these two factors. Third, the number of children in each community who are pedal cyclists is unknown, limiting injury rate comparisons between communities. Fourth, the assessment of the effect of bicycle helmet legislation was restricted by the small population affected by these laws. Fifth, this analysis did not distinguish between head and neck injuries. Finally, only the primary diagnosis was included in the analysis; head and neck injuries that were not primary diagnoses were excluded, potentially underestimating the total number of head and neck injuries.
Even young children are at risk for injuries from pedal-cycle injuries, which are predominantly head and neck injuries. Helmets might protect children from a subset of these injuries because helmets have been determined to prevent pedalcycle-related head and facial injuries (2) . Children aged <1 year should not be transported on a pedal cycle because they lack the neck strength to support a helmet (10) . When fitted properly, the front part of the helmet should be low on the forehead so that if the child falls forward, the helmet strikes first, protecting the head and much of the upper face from impact. Although measures to improve bicycle safety often focus on teaching helmet use and safe bicycling techniques to children aged >5 years (1), the findings in this report demonstrate that potentially preventable injuries occur among children at younger ages.
Measles -United States, 2005
Measles is a highly infectious, acute viral illness that can be complicated by severe pneumonia, diarrhea, and encephalitis and can result in death. In the prevaccine era, approximately 500,000 cases of measles occurred annually in the United States (1) . During 2005, local and state health departments reported to CDC 66 confirmed cases of measles (incidence rate: less than one case per 1 million population), 34 of which were from a single outbreak in Indiana associated with infection in a traveler returning to the United States. This report describes the epidemiology of U.S. measles cases in 2005 and documents the absence of endemic measles and the continued risk for imported measles infections that can result in transmission within the United States. The findings underscore the need to maintain the highest possible measles vaccination coverage in the United States and to adhere to recommendations regarding measles vaccination.
Case Classification
In accordance with state laws and regulations, health-care providers, laboratories, and other health-care workers report measles cases to state and public health departments; this information is forwarded to CDC. Data on variables such as vaccination status, age, complications, transmission setting, and serologic confirmation of cases also are collected.
In 2005, of the 66 cases reported, 44 (66%) were confirmed by laboratory testing, including 19 with detection of both IgM antibodies and virus (by polymerase chain reaction, culture, or both) and 25 with only measles IgM detected. The remaining 22 (33%) were confirmed by meeting the clinical case definition* and by being linked epidemiologically to a laboratory-confirmed case.
Twenty-four (36%) of the 66 infections were imported, † including 17 (71%) in U.S. residents who acquired measles while traveling abroad and seven (29%) in non-U.S. residents who acquired the disease abroad and traveled to the United States. Measles was imported from 16 countries on four continents. § Of the 24 patients with imported measles, eight (33%) were infectious during airline flights (i.e., rash onset occurred some time during the period 4 days before through 4 days after date of U.S. arrival). No secondary transmission was identified among flight crew members or passengers seated in the same row or the row in front of or behind the infectious person.
The other 42 (64%) cases were U.S. acquired, ¶ of which 38 (90%) were import linked and four (10%) had unknown sources of exposure. Thirty-three (87%) of the 38 importlinked cases were part of a single outbreak in Indiana, traced to exposure in Romania. Of the remaining five import-linked cases, two patients were linked to measles imported from Nigeria, and three were linked to only one other case. Overall, 62 (94%) of the 66 cases in 2005 were determined to be import associated (i.e., either imported or U.S. acquired but import linked).
Age and Sex Distribution
Distribution of the 66 measles patients by age group was as follows: seven (10.6%) measles patients were aged <1 year, four (6.1%) 1-4 years, 33 (50%) 5-19 years, seven (10.6%) 20-34 years, and 15 (22.7%) >35 years. Thirty-one (47%) patients were male, and 34 (52%) were female; the sex of one patient was not recorded.
Geographic and Temporal Distribution
The 66 cases were reported from 16 states. Five states reported more than two cases: Indiana (33 cases), New York (seven cases, including six from New York City), California (four cases), and Texas and Ohio (three cases each).
Cases were reported during 28 of the 52 reporting weeks (Figure) . The longest period during which no cases were reported was 8 weeks, from week 38 through week 45. The median number of cases reported per week was one (range: zero to 14 cases). The maximum number of cases reported during a single week was 14 (week 22).
Vaccination Status
Of the 66 persons with measles, one had been vaccinated with 2 doses of a measles-containing vaccine and seven (11%) with 1 dose; 50 (76%) were unvaccinated, and eight (12%) had unknown vaccination status (Table) . Fifteen of the 17 U.S. residents who acquired infection while traveling abroad had been eligible for vaccination with 2 doses of measlescontaining vaccine, according to recommendations from the Advisory Committee on Immunization Practices (ACIP) (4). * Generalized maculopapular rash lasting >3 days with fever >101.0 º F (>38.3 º C) and one of the following: cough, coryza, or conjunctivitis (2). † Cases among persons who were exposed and infected outside the United States (3). § Asia, 13 cases: India and Saudi Arabia had two each; Armenia, Bangladesh, China, Indonesia, Pakistan, Thailand, and Yemen had one each; and two persons traveled to more than one country in Southeast Asia. Europe, six cases: Germany and Romania, two each; Belgium and France, one each. North America, three cases: Mexico, three. Africa, two cases: Kenya and Nigeria, one each. ¶ U.S.-acquired cases are those in persons infected in the United States. These cases are subclassified into four groups: import linked (i.e., epidemiologically linked to an imported case); imported virus (i.e., cases that cannot be linked epidemiologically to an imported case but for which viral genetic evidence indicates an imported measles genotype); endemic (i.e., cases for which epidemiologic or virologic evidence indicates a chain of measles virus transmission that is continuous for >12 months within the United States); and unknown source (i.e., all other cases acquired in the United States for which an epidemiologic or virologic link to importation or to endemic transmission within the United States cannot be established after a thorough investigation) (3).
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However, four (27%) had been vaccinated with only 1 dose; eight (53%) had not been vaccinated (including three infants aged 11-12 months), and three (20%) had unknown vaccination status. Two of the 17 U.S. residents were ineligible because they were born before 1957 (one had not been vaccinated; the other had unknown vaccination status). Of the seven visitors (non-U.S. residents) with imported measles, one (14%) had been vaccinated with 1 dose; four (57%) had not been vaccinated (including one infant aged 8 months), and two (29%) had unknown vaccination status. Among the 42 U.S.-acquired cases, one patient had been vaccinated with 2 doses; two (5%) patients had been vaccinated with 1 dose, and 37 (88%) had not been vaccinated (including 29 [69%] persons aged 1-19 years). The vaccination status of two patients (5%) was not known.
Outbreaks
During 2005, three measles outbreaks (i.e., with three or more epidemiologically linked cases) were reported to CDC. These outbreaks affected three states and accounted for 40 (61%) of the 66 reported cases. An outbreak in Indiana with 34 cases (including one Illinois resident) resulted from an unvaccinated U.S. resident aged 17 years who returned home after acquiring measles infection in Romania. Of the 34 patients in this outbreak, 32 (94%) were eligible for vaccination. Of these, one patient aged 16 years had been vaccinated with 2 doses, a health-care worker aged 34 years had been vaccinated with only 1 dose, and 28 (88%) patients aged 1-19 years had not been vaccinated, primarily because their parents were concerned about potential adverse events associated with vaccination. Vaccination status for two patients, aged 43 and 45 years, was unknown. Two other patients were ineligible because of their ages: one was aged <12 months, and the other was born before 1957 and presumed immune to measles. Among the school-age patients (aged 5-19 years), 20 (71%) were schooled at home. Three persons were hospitalized during this outbreak, including the health-care worker, who was treated in the intensive care unit and recovered (5, 6) .
A second outbreak was traced to a visitor aged 6 years from Nigeria, who was hospitalized in Ohio. Cases of measles in two U.S. residents, an unvaccinated health-care worker and an unvaccinated person aged 89 years, were linked to the hospital setting. A third outbreak involved three U.S residents, two adults and a child aged 20 months, who had traveled together to a family reunion in Mexico and might have been exposed during air travel before returning to Texas. The adults had been vaccinated; the child had not been vaccinated.
Viral Genotypes
Five genotypes of measles virus were identified in specimens from 19 patients representing 11 importations. Genotype D4 was identified in two travelers to France and Germany, two visitors from Romania and Yemen, and eight patients with U.S.-acquired measles linked to an imported case from Romania (the Indiana outbreak). Genotype B3 was identified in a refugee from Kenya and two of the three U.S. travelers to Mexico (7) . Genotype D8 was identified in two U.S. residents returning from India. Genotypes D6 and D9 were isolated from a foreign visitor from Armenia and a child returning from Indonesia, respectively. Measles viruses in the four U.S.-acquired cases with unknown sources were not genotyped.
Editorial Note: The epidemiology of measles in 2005 supports previous conclusions that endemic transmission of measles has been eliminated in the United States (8, 9) . Measles incidence was low (less than one case per million population), measles cases were geographically isolated, and 95% of cases were linked to importations (i.e., internationally imported or U.S-acquired, import-linked cases). In addition, no predominant and recurring viral genotype was detected, and the measles genotypes detected, in most circumstances, had been circulating within the country of presumed exposure (10) .
Half of all the cases in 2005 are traceable to one unvaccinated U.S. resident, who was infected during a visit to Romania of less than 2 weeks. This outbreak was the largest documented in the United States since 1996. All but two of the 34 patients in this outbreak were unvaccinated. The outbreak occurred because measles was imported into a population of children whose parents had chosen not to vaccinate their children because of safety concerns, despite evidence that that measles-containing vaccine is safe and effective (4). A major epidemic was averted because of high vaccination levels and a low rate of vaccine failure in the surrounding community. The cost of containing this outbreak was estimated at $167,685 (5) . This outbreak and other cases reported during 2005 likely could have been prevented had existing ACIP vaccination recommendations been followed (4) . The index case traveler should have been vaccinated with 2 doses of measlescontaining vaccine before departure; exposed school-age children and personnel working in health-care facilities also should have had the recommended 2 doses before exposure.
The epidemiology of measles in 2005 highlights the need to maintain the highest possible measles vaccination coverage in the United States and to continue to address the concerns of those who choose not to be vaccinated or who choose not to vaccinate their children. Because 100% coverage in U.S. residents might never be achieved and because communities of unvaccinated persons continue to exist, accurate surveillance and rapid response to outbreaks are essential to preventing widespread transmission of imported measles. Moreover, providing assistance to other countries to control measles globally can limit the risk for imported measles in the United States.
Use of Cessation Methods Among Smokers Aged 16-24 YearsUnited States, 2003
Smoking cessation among adolescent smokers is relatively rare, with approximately 15.6% of smokers aged 12-19 years quitting smoking in a 4-year period (approximately 4% per year) (1) . Rates for failed quitting attempts among younger smokers are higher than those for adults (43%) (2) , with approximately 58% of high-school smokers having tried to quit at least once for 1 day or longer in the preceding year (3) . To track the history of quitting behavior among smokers aged 16-24 years, Roswell Park Cancer Institute (Buffalo, New York) initiated the 2-year longitudinal National Youth Smoking Cessation Survey (NYSCS)* in 2003. This report summarizes key findings from the survey regarding lifetime use of smoking-cessation methods. The findings indicated that smokers aged 16-24 years who had tried to quit were more likely to use unassisted quitting methods than assisted quitting methods; none of the unassisted methods are recommended by the Public Health Service (PHS) clinical guidelines for treatment of tobacco use and dependence, whereas most of the assisted methods are recommended for adults and have been determined to be effective. Many youths aged 16-24 years are trying to quit smoking but often underestimate the rapid progression to tobacco dependence; therefore, PHS clinical practice guidelines for treating tobacco use and dependence recommend that certain clinical interventions proven to be effective among adults be used in youth-based approaches to cessation (4) . In addition, other components of comprehensive tobacco-control programs also increase smoking cessation and should be implemented at CDC-recommended levels (5) to lower tobacco use among youths and adults.
The 2003 NYSCS collected information on tobacco use and quitting practices through a random-digit-dialed, computer-assisted telephone interview survey of young smokers conducted by Westat (Rockville, Maryland) during JuneNovember 2003. Persons aged 16-24 years who had smoked at least 20 cigarettes in their lifetimes and who had smoked at least once during the preceding 30 days were interviewed from randomly selected U.S. households with telephones. A total of 2,582 respondents completed the initial interview (69.6% response rate for all age-eligible smokers). † Smokers who had ever tried to quit were asked about their knowledge of, the perceived availability of, and use of assisted and unassisted quitting methods. Assisted methods include medications or obtaining assistance from a person, class, telephone counselor, or website. Respondents who were knowledgeable about a specific assisted method and perceived that the method was available were then asked whether they had ever used that method. Respondents who had ever tried to quit also were asked about their use of unassisted methods to quit smoking, including using self-help strategies and educational methods, such as pamphlets/videos, exercising, and changing smokingrelated behaviors (e.g., decreasing the number of cigarettes smoked or not buying cigarettes).
* Funded by the Robert Wood Johnson Foundation, with additional analytical support provided by the National Cancer Institute and CDC. † Of 85,000 households in the sample, 60.0% responded, and 21.4% of the responding households had one or more persons aged 16-24 years. Respondents were given a reward for participation worth $20 (either a check, restaurant coupons, or a store gift certificate).
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Data were weighted to represent the population of U.S. smokers aged 16-24 years, according to the [2001] [2002] Tobacco Use Supplement to the Current Population Survey. To ensure that respondents being analyzed were established smokers and had attempted to quit, only those who had smoked at least 100 cigarettes during their lifetimes and who had tried to quit smoking at least once were included in the analyses (1,827 respondents). Use of methods to quit also was examined by sex.
Of the 13 assisted methods (Table 1) , only one (talking with a nurse, doctor, or dentist) was used by at least 20% of this age group, whereas six of the 11 unassisted (i.e., not recommended by PHS guidelines) methods were each used by at least 36% of respondents ( Table 2 ). The most commonly used unassisted strategy (decreasing the number of cigarettes smoked) was tried by 88.3% of young smokers. The remaining five frequently used unassisted strategies were not buying cigarettes (56.0%), exercising more (51.0%), trying to quit with a friend (47.5%), telling others they no longer smoked (44.5%), and switching to light cigarettes (36.1%).
Females (24.9%) were more likely than males (15.6%) to seek help from health professionals but less likely to have tried nicotine gum (14.4% versus 20.3%) ( Table 1) . Females (52.1%) also were more likely than males (43.2%) to try to quit with a friend and to have used self-help pamphlets or videos (19.5% versus 12.5%). However, males (55.7%) were more likely than females (46.0%) to exercise more as a strategy to quit and to switch to chewing tobacco, snuff, or other tobacco products (18.0% versus 1.6%) ( Table 2 ).
Editorial Note:
The NYSCS results indicate that smokers aged 16-24 years rely more on unassisted methods to try to quit than assisted methods recommended for adults by PHS clinical guidelines (4) . The following six cessation methods are recommended by PHS for adults: 1) talk with a health professional, 2) use nicotine-replacement products, 3) use bupropion, 4) talk with a counselor, 5) attend a program or class, and 6) call a telephone helpline. Among NYSCS respondents, only 20.1% who had ever tried to quit had ever spoken with a health-care professional about quitting, the most commonly used assisted method. Among adult smokers who had been to a health-care professional and tried to quit during a given year, 61.8% were advised to quit using tobacco products (6). Female respondents also were more likely than male respondents (24.9% versus 15.6%) to have talked with a health-care professional; this finding might be directly related to a difference in the number of visits typically made by young males and females to health-care professionals, a difference that has been reported for adults (7) . Use of certain unassisted strategies such as switching to light cigarettes or switching to chewing tobacco, snuff, or other tobacco products was common. The high proportion of respondents who tried to quit smoking by switching to light cigarettes (36.1% overall) or other tobacco products (18.0% among males) is a concern because such strategies might undermine successful cessation (8) .
The findings in this report are subject to at least two limitations. First, these nationally representative estimates apply only to smokers aged 16-24 years living in households with telephones. Second, respondents were asked to identify themselves as smokers or nonsmokers and did not submit to any biochemical validation; some smokers might not have identified themselves as such. During the initial questions of the interview, respondents were unaware that participation in the survey was limited to smokers.
Because of the lack of sufficient evidence regarding the effectiveness of interventions for smokers aged 16-24 years, persons such as public health practitioners and health-care providers who work with smokers in this age range should consult CDC's Youth Tobacco Cessation: A Guide for Making Informed Decisions, which summarizes what is known about tobacco-cessation interventions for youth and the role of these interventions in comprehensive tobacco-control programs (9) . Clinical interventions that apply cognitive-behavioral approaches to behavior change seem the most promising (10). Additional research is needed to find effective clinical cessation interventions to help young persons stop smoking. For smokers aged <18 years, effective behavioral counseling approaches are essential because the Food and Drug Administration has not approved the use of any pharmacotherapy (e.g., nicotine-replacement products or bupropion) for smoking cessation in this age group. As these potential interventions are being researched and developed, comprehensive tobaccocontrol programs, which also include nonclinical interventions such as increasing excise taxes, promoting smoke-free air policies, conducting media campaigns with other community-based interventions, providing insurance coverage for proven treatments, and establishing telephone helplines, should be fully implemented in every state and territory to prevent youths from starting to smoke and to help youths and adults stop smoking (5). 
CDC's 60th Anniversary
Director's PerspectiveJames O. Mason, M.D., Dr.P.H.,
1983-1989 New Responsibilities Bring New Challenges
The growing momentum toward expanding CDC's responsibilities beyond infectious diseases gained strength during the 1980s. Tremendous advances in controlling infectious diseases had dramatically reduced illness and death from many longstanding health threats. In addition, the detrimental effects of chronic and other noncommunicable diseases on the nation's health were rapidly increasing. Programs to address cancer, heart disease, diabetes, and other leading killers became central to CDC's focus. Yet, for much of this decade, a newly emerging infectious disease would demand the skills and talents of persons across the agency. These new responsibilities led to additional funding, programs, staff, and partnerships for the growing agency, while introducing a host of new challenges.
Preventing Chronic Diseases
Among the most targeted causes of chronic diseases was smoking. Steps to reduce the harmful effects of tobacco products had steadily increased throughout the U.S. Department of Health and Human Services (DHHS). CDC was heavily involved in these activities and faced pressures from industry and political fronts. In October 1984, Congress enacted the first major legislation on smoking and health in 15 years, the Comprehensive Smoking Education Act, Public Law 98-474. This legislation required stronger and more specific health warnings on all cigarette packages and advertisements and outlined specific responsibilities for DHHS. Among these were directives to expand activities on smoking and health and to issue a biennial report to Congress. In 1986, the DHHS Office on Smoking and Health was transferred to CDC and joined with CDC's programs to produce the first of these reports, Smoking and Health: A National Status Report (1), providing a comprehensive look at this important public health problem across national, state, and local levels. In his cover letter distributing the report to Congress, the Secretary of Health and Human Services urged all jurisdictions to adopt a minimum age of 18 years for persons to legally purchase tobacco products, stating that "Enactment and enforcement of such legislation could have a strong preventive effect on early uptake of cigarettes and other tobacco products." Included in the report were findings that 12 states had no age-related tobacco restrictions, and 14 of those with such laws had set the minimum age for purchasing tobacco products at younger than 18 years. The agency's expanding smoking-related programs advanced plans to create a chronic disease center at CDC, and in 1988, the Center for Chronic Disease Prevention and Health Promotion became a reality.
Focus on Injury and Violence
CDC's programs to prevent injury and violence also were gaining prominence. As had been shown with chronic diseases, many of the same tools that had long proven effective in preventing and reducing infectious diseases (e.g., surveillance, epidemiologic research, education, and communication) could be used to address both unintentional and intentional injuries. In 1985, the Institute of Medicine published a report, Injury in America: A Continuing Public Health Problem (2), drawing attention to and recommending steps to stem this rising public health problem; among these steps was the establishment of a center for injury control at CDC. Broadening their expertise, CDC's violence program within the Center for Health Promotion and Education joined with CDC's injury program in 1986 to become the Division of Injury Prevention and Control in the Center for Environmental
In commemoration of CDC's 60th Anniversary, MMWR is departing from its usual report format. This is the third in a series of occasional commentaries by directors of CDC. The directors were invited to give their personal perspectives on the key public health achievements and challenges that occurred during their tenures.
Health. Through this division, CDC undertook additional steps to address these alarming threats (e.g., homicide, suicide, and motor-vehicle traffic deaths), including funding of injury control research centers at universities throughout the country to conduct research in prevention, acute care, and rehabilitation. These measures paved the way for establishment of the National Center for Injury Prevention and Control at CDC in 1992.
Agent Orange Studies
As Bill Foege described in his Director's Perspective (3), CDC's expanding work toward reducing noninfectious health conditions brought with it many new challenges. Under legislation enacted in 1979 and 1981, Congress directed the Veterans Administration (VA) to conduct investigations into the health of U.S. Vietnam veterans in response to growing concerns from veterans that exposure to the defoliant mixture "Agent Orange," used widely in Vietnam, had affected their health and that of their children. In January 1983, CDC was assigned responsibility through an interagency agreement with the VA for designing, conducting, and analyzing data from these studies. Under authorization from Congress, CDC began three epidemiologic studies: the Agent Orange Exposure Study designed to evaluate the long-term health effects of exposure to herbicides, particularly Agent Orange, among Vietnam veterans; 2) the Vietnam Experience Study, a comprehensive study examining the occurrence of adverse health effects among Vietnam veterans; and 3) the Selected Cancers Study to determine whether Vietnam veterans were at increased risk for certain types of cancers possibly related to exposure to dioxin, a contaminant found in Agent Orange.
The Agent Orange Exposure Study was abandoned as unfeasible in 1987. Validation testing in a sample of veterans who served in Vietnam at the time and location of heaviest Agent Orange spraying found that none of the indirect methods for assessing exposure showed any meaningful association with current levels of dioxin in blood. Moreover, no method could be identified for using military records or self-reported exposure to distinguish between U.S. Army ground combat troops who were and were not exposed to Agent Orange in Vietnam.
The Vietnam Experience Study went beyond herbicide exposure to examine many factors that could have adversely affected Vietnam veterans, including the psychological stresses of war, possible exposure to various infectious diseases, reproductive outcomes, and possible misuse of drugs and alcohol. The study involved more than 7,000 men who had served in Vietnam during 1965-1971 and a similar number of veterans who had served elsewhere during the same period. The study found that the Vietnam veterans more frequently reported health problems for themselves and their children, compared with the non-Vietnam veterans, but very few differences between the two groups were found on medical and laboratory examinations, including hospital birth records. However, problems such as depression, anxiety, and combatrelated post-traumatic stress disorder were found to be more common among the Vietnam veterans (4).
The Selected Cancers Study assessed the risk for nonHodgkin's lymphoma, soft tissue sarcoma, Hodgkin's disease, nasopharyngeal cancer, and primary
Emergence of AIDS Brings Unprecedented Public Health Conflict
The formidable challenges presented by CDC's broadening responsibilities underscored the importance of strictly adhering to science in presenting findings and developing policy. This lesson would prove even more critical as a new infectious disease began emerging in young, homosexual men in the United States, challenging the public health community in unforeseen ways and eventually changing world health. Fully entrenched by the time it was recognized in 1981, the disease, eventually given the name acquired immunodeficiency syndrome (AIDS), reintroduced the public to fear of infectious diseases and divided the country across social, religious, and political lines.
Before AIDS, public fear of infectious diseases had largely subsided because of the availability and widespread use of vaccines and antibiotics. Many believed most infectious diseases were curable and no longer life-threatening, affording a new level of health not enjoyed by previous generations. AIDS abruptly corrected this misperception (Figure 1 ), emerging as a new health threat with devastating consequences and a host of medical, ethical, legal, and economic implications.
Developing Evidence-Based Guidelines
Not only was the new condition baffling, the myriad associated diseases, termed "opportunistic infections" because they were usually only seen in persons with drug-suppressed or otherwise severely compromised immune systems, were unfamiliar to most physicians and scientists. However, within 1 year of the first case reports, a case definition had been developed and all major routes of transmission had been identified. In March 1983, CDC published the first set of guidelines for preventing the disease (5). Based on the best available science at the time, these recommendations proved essentially correct and have not been revised significantly.
In 1984, the cause of the disease was determined to be a previously unrecognized retrovirus, first termed human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) and later renamed human immunodeficiency virus (HIV). In March 1985, a test to detect antibodies to the virus was licensed by the Food and Drug Administration (FDA) for use in screening donated blood and plasma. Although the test was not approved for individual testing, public health officials recognized that many at-risk persons would seek testing at blood banks to learn their infection status. By this time, sufficient funds had been authorized by Congress to enable CDC to begin funding AIDS prevention activities in state and local health departments. Through cooperative agreements, CDC awarded funds to 55 state and local health departments to establish alternate testing sites for at-risk persons to obtain antibody tests free of charge outside the blood-bank setting. Such sites were established both to decrease potential false-negative donations and to ensure that persons wishing to be tested would receive appropriate preand post-test counseling and referrals. Use of the antibody test for individual testing was approved by FDA in 1986. The ability to test persons for the virus offered new opportunities for prevention and for treatment to possibly delay the onset of the disease. Unfortunately, this medical advancement also unleashed a new set of fears among an already stigmatized population, especially regarding increased discriminatory actions related to education, employment, health care, and insurance.
Scientifically, these early years of AIDS were characterized by unprecedented progress toward understanding a new, highly complex infectious disease. In 1985, the first AIDS conference was held, and the World Health Organization formed a network of AIDS collaborating centers. By the end of 1986, CDC had published nearly 100 MMWR reports related to AIDS. These reports included recommendations to prevent transmission of the virus through transfusions, transplants, patient care, and perinatal exposure; workplace and schoolbased guidelines; and critical reports from state and local health departments outlining the epidemic's impact in their areas. CDC's AIDS surveillance programs were among the most comprehensive disease-tracking measures ever undertaken. These programs yielded data that highlighted growing epidemics outside of major metropolitan areas and among minority populations, allowing for more targeted prevention measures and funding.
Fear Affects Public Policy
Despite solid scientific advances, no epidemic in history has engendered a greater level of controversy. Divisive views over the epidemic's earliest and most severely affected populations, homosexual/bisexual men and intravenous drug users, undoubtedly hindered progress on many fronts, including risk communication and funding for prevention and research. Some in Congress claimed that AIDS spending was exorbitant, disproportional to the magnitude of the problem, while others argued that inadequate funding was slowing research on testing, treatment, and vaccine development. The public also became involved in these disputes, disagreeing on transmission risks, populations that should be tested, and restrictions on infected persons. The media fueled their interests. In describing results from a 1985 poll of more than 2,000 persons, the New York Times reported that "51 percent of the respondents supported a quarantine of acquired immune deficiency syndrome patients, 48 percent would approve identity cards for those who have taken tests indicating the presence of AIDS antibodies, and 15 percent supported tattooing those with AIDS" (6) .
Although these arguments were vocalized as focusing on rights of the public versus rights of AIDS patients, in reality they were driven by fear. The medical and scientific Year Rate community had difficulty communicating the risks associated with this new disease with the same level of certainty demanded by the public. Studies conducted among family members of AIDS patients had provided strong evidence of the lack of transmission from casual contact. However, many persons, including lawmakers, believed otherwise and were not readily dissuaded.
In particular, school attendance by children with AIDS was the subject of intense debate. CDC's 1985 recommendations on education and foster care for children with HIV/AIDS stated that decisions regarding the type of education and care setting for infected children should be made on an individual basis but that "For most infected school-aged children, the benefits of an unrestricted setting would outweigh the risks of their acquiring potentially harmful infections in the setting and the apparent nonexistent risk of transmission of HTLV-III/LAV" (7). Soon after the release of these guidelines in late August 1985, the Washington Post ran an op-ed piece entitled, "Worry about the Survival of Society First; Then AIDS Victims' Rights," which was picked up by newspapers across the country (8, 9) . Playing to the public's fear and skepticism, the editorial argued that many of the laws that had been enacted to protect AIDS patients from discrimination were misguided and cited CDC's recent guidelines as remiss.
In many areas of the country, these recommendations were met with staunch opposition. In Florida, the parents of three HIV-infected hemophilic sons, Ricky, Robert, and Randy Ray, were plaintiffs in a federal lawsuit against their local school board to allow their children to attend public school. A week after the court's ruling in favor of the Rays, their home was burned down. In Indiana, the experiences endured by a young man named Ryan White would ultimately change public opinion on AIDS throughout the world and lead to specifically designated federal resources for AIDS patients through the 1990 Ryan White Comprehensive AIDS Resources Emergency (CARE) Act.
At CDC, measures to expand surveillance and case reporting and to develop new prevention guidelines required dedicated consensus building that went beyond the medical and scientific community to include affected persons, special interest and political groups, and the public. Throughout these processes, CDC worked to ensure that these new recommendations and guidelines reflected the best available science, a commitment that has served public health well. For example, CDC's 1988 recommendations for preventing HIV transmission in health-care settings (10) recommended that blood and certain body fluids from every single patient be viewed as potentially infectious for HIV or other bloodborne pathogens. These guidelines became known as "universal blood and body fluid precautions" or "universal precautions" and led to permanent changes in health-care practices throughout the world.
Strengthening State and Local Public Health Infrastructures
By the mid-1980s, both funding and political support were available to launch widespread public information campaigns, viewed as critical in stemming the epidemic and enabling those already infected to receive treatment and other services. CDC's National AIDS Hotline was started in 1983 to enhance surveillance for the disease, but its role quickly expanded to address the urgent need for disseminating accurate and timely information. In 1987, CDC established the National AIDS Clearinghouse to distribute printed materials on AIDS. The same year, CDC launched America Responds to AIDS, a substantial, nationwide public information campaign that had been developed through extensive formative research (11). Over the next 4 years, five separate phases of informational materials were developed and released to the general public, ranging from basic information on the disease to specific information for different risk groups. The largest of these came in 1988, when more than 107 million copies of the brochure Understanding AIDS were delivered to homes and residential post office boxes in the United States (Figure 2) . A Spanishlanguage version also was distributed in Puerto Rico and other predominantly Spanish-speaking areas. The brochure, developed by CDC in consultation with Surgeon General C. Everett Koop, other health experts, and public citizens, marked the first time the federal government had attempted to contact every resident directly by mail regarding a public health problem (12). Koop's open stance against smoking had made him a well-recognized public health official, and his commitment to educating the public on HIV/AIDS made him a highly effective and credible spokesperson in this effort.
In addition to expanded funding for AIDS surveillance and prevention activities at state and local health departments, CDC began funding national and regional minority organizations, community-based organizations, and the faith-based community for these activities in 1988-1989. This increased funding for extramural activities is reflected in CDC's budget for those years, which nearly tripled from fiscal years 1983-1989 ( Figure 3 ) without a commensurate increase in full-time employees (Figure 4) . The systems and services developed and implemented in response to the AIDS epidemic helped build and maintain public health infrastructures at multiple levels and would improve capabilities and serve as a model for other disease detection and prevention measures.
During 1981-1989, more than 100,000 cases of AIDS in the United States were reported to CDC, approximately one third of them in 1989 alone (13). Although cases were reported from all 50 states, the District of Columbia, and four U.S. territories, two thirds of the cases were reported from five states: New York, New Jersey, Florida, Texas, and California. In addition, although the epidemic had spread beyond the earliest risk groups of homosexual/bisexual men and intravenous drug users, these groups continued to account for nearly 90% of cases. Today, the epidemic's global impact is staggering, with nearly 40 million persons living with HIV throughout the world (14). The fear of the disease that so adversely affected the U.S. response during the early years of the epidemic has largely subsided in this country, dissolving much of the resistance to new policies and procedures and enabling better acceptance and delivery of new prevention and treatment strategies. A clear example of this change is reflected in CDC's new HIVtesting recommendations (15). Published in September 2006, these evidence-based recommendations call for nearly universal testing of patients in health-care settings, a strategy that would not have been possible to put forward as recently as a decade ago. In many of the world's most heavily affected regions, however, fear and lack of education about the disease continue to impede prevention measures and stigmatize infected persons. As new funding and partners are united globally to address the pandemic, primary prevention measures must first focus on ending the fear.
An Expanded Agency
Change, expansion, and growing domestic and international visibility characterized CDC's fourth decade. Exacting science and honest risk communication proved to be the agency's most effective prevention tools. Lessons learned from past successes and challenges will serve CDC well as its roles and responsibilities toward protecting the nation's health continue to expand. 
Update: Influenza ActivityUnited States, October 1-December 9, 2006
During October 1-December 9, 2006, influenza activity remained low in the United States overall but increased in southeastern states. This report summarizes U.S. influenza activity* since October 1, the beginning of the 2006-07 influenza season, and updates the previous summary (1).
Viral Surveillance
During October 1-December 9, 2006, † the World Health Organization (WHO) and National Respiratory and Enteric Virus Surveillance System collaborating laboratories in the United States tested 27,474 specimens for influenza viruses, and 884 (3.2%) were positive ( Figure 1 ). Of these, 689 (77.9%) were influenza A viruses and 195 (22.1%) were influenza B viruses. A total of 171 (24.8%) of the 689 influenza A viruses were subtyped; 162 (94.7%) of these were influenza A (H1) viruses, and nine (5.3%) were influenza A (H3) viruses. Influenza-positive tests were reported from 37 states in all nine surveillance regions; 441 (49.9%) of the 884 positive tests were reported from Florida. ILI during non-influenza weeks for the preceding three seasons plus two standard deviations. A non-influenza week is a week during which <10% of specimens tested positive for influenza. National and regional percentages of patient visits for ILI are weighted on the basis of state population.
Use of the national baseline for regional data is not appropriate. 
Influenza-Like Illness (ILI) Surveillance
During the current influenza surveillance season, weekly percentages of patient visits for ILI § reported by approximately 1,300 U.S. sentinel providers in 50 states, New York City, Chicago, and the District of Columbia have ranged from 1.1% to 1.9%. During the week ending December 9, the percentage of patient visits for ILI was 1.9%, which is below the national baseline of 2.1% ¶ (Figure 2 ). Two regions have reported ILI above their region-specific baselines this season. For the week ending December 9, the East South Central region reported that 2.6% of patient visits were for ILI, compared with its baseline of 2.4%; the West South Central region reported 3.2%, compared with its baseline of 3.0%. § Defined as a temperature of >100.0 º F (>37.8 º C), oral or equivalent, and cough and/or sore throat, in the absence of a known cause other than influenza. ¶ The national and regional baselines are the mean percentage of visits for ILI during non-influenza weeks for the previous three seasons plus two standard deviations. A non-influenza week is a week during which <10% of specimens tested positive for influenza. National and regional percentages of patient visits for ILI are weighted on the basis of state population. Use of the national baseline for regional data is not appropriate. ** Levels of activity are 1) no activity; 2) sporadic: isolated laboratory-confirmed influenza cases or a laboratory-confirmed outbreak in one institution, with no increase in activity; 3) local: increased ILI, or at least two institutional outbreaks (ILI or laboratory-confirmed influenza) in one region with recent laboratory evidence of influenza in that region; virus activity no greater than sporadic in other regions; 4) regional: increased ILI activity or institutional outbreaks (ILI or laboratory-confirmed influenza) in at least two but less than half of the regions in the state with recent laboratory evidence of influenza in those regions; and 5) widespread: increased ILI activity or institutional outbreaks (ILI or laboratory-confirmed influenza) in at least half the regions in the state with recent laboratory evidence of influenza in the state.
These reports marked the second week that the East South Central region has been at or above baseline and the fifth consecutive week for the West South Central region.
State-Specific Activity Levels
During the week ending December 9, 2006, influenza activity was reported as widespread** in one state (Florida) (Figure 3 ). In addition, three states reported regional activity (Alabama, Georgia, and South Carolina); seven states reported local activity ( 
No report
Regional Widespread * Levels of activity are 1) no activity; 2) sporadic: isolated laboratoryconfirmed influenza cases or a laboratory-confirmed outbreak in one institution, with no increase in activity; 3) local: increased influenza-like illness (ILI), or at least two institutional outbreaks (ILI or laboratoryconfirmed influenza) in one region with recent laboratory evidence of influenza in that region; virus activity no greater than sporadic in other regions; 4) regional: increased ILI activity or institutional outbreaks (ILI or laboratory-confirmed influenza) in at least two but less than half of the regions in the state with recent laboratory evidence of influenza in those regions; and 5) widespread: increased ILI activity or institutional outbreaks (ILI or laboratory-confirmed influenza) in at least half the regions in the state with recent laboratory evidence of influenza in the state. 30  40  50  10  20  30  40  50  10  20  30  40  50  10  20  30  40  50 Virginia, Washington, West Virginia, Wisconsin, and Wyoming); and the District of Columbia and nine states reported no activity (Kansas, Maine, Missouri, Nebraska, Nevada, New Jersey, New Mexico, South Dakota, and Vermont). Regional influenza activity was reported for the first time this season during week 44 (by North Carolina), and widespread activity was reported for the first time during week 47 (by Alabama). To date this season, regional or widespread influenza activity has been reported by only six states (Alabama, Florida, Georgia, Mississippi, North Carolina, and South Carolina), all in the southeastern area of the country. Influenza outbreaks have been reported by Alabama, Florida, and North Carolina, with most cases occurring among children.
Influenza-Associated Pediatric Hospitalizations
Pediatric hospitalizations associated with laboratoryconfirmed influenza infections are monitored by two population-based surveillance networks, the Emerging Infections Program (EIP) and the New Vaccine Surveillance Network (NVSN). No influenza-associated pediatric hospitalizations have been reported from either network yet this season. † †
Pneumonia-and Influenza-Related Mortality
For the reporting week December 3-9, 2006, pneumonia and influenza (P&I) was listed as an underlying or contributing cause of death for 6.3% of all deaths reported through the 122 Cities Mortality Reporting System (Figure 4 ). During the current influenza season, the weekly percentage of deaths attributed to P&I has ranged from 5.6% to 6.3% and has not exceeded the epidemic threshold for any week. § §
Influenza-Related Pediatric Mortality
No influenza-related pediatric deaths have been reported through the National Notifiable Diseases Surveillance System for the 2006-2007 influenza season. Editorial Note: During October 1-December 9, 2006, the United States experienced a low level of influenza activity. Widespread and regional activity was reported in only six states in the southeastern area of the country. Outbreaks were reported primarily among children in Alabama, Florida, and North Carolina. Influenza virus isolates have been reported in all nine surveillance regions in the United States. Patient visits for ILI, represented by the Sentinel Provider Surveillance Network, and P&I mortality, represented by the 122 Cities Mortality Reporting System, have not exceeded national baseline levels. In addition, no influenza-associated hospitalizations from the EIP or NVSN surveillance systems have been reported to CDC and no influenza-related pediatric deaths have been reported through the National Notifiable Diseases Surveillance System.
Vaccination is the best method for prevention of influenza and its potentially severe complications. Although the optimal months for influenza vaccination are October and November, vaccination in December and beyond is recommended because influenza activity peaks in January or later during most seasons (2) . The degree of antigenic match between the current vaccine strains and strains that will circulate this season will be determined as more strains become available for analysis. To date, influenza A (H1) viruses have been reported most frequently, and the majority of influenza A (H1) viruses characterized are well matched by the vaccine.
Influenza vaccine can be administered to any person who wants to reduce the likelihood of becoming ill with influenza. Annual influenza vaccination is particularly targeted toward persons at increased risk for influenza-related complications and severe disease (e.g., children aged 6-59 months, pregnant women, persons aged >50 years, and persons aged 6 months-49 years with certain chronic medical conditions) and their close contacts (e.g., health-care workers and household contacts of persons at increased risk, including contacts of children aged <6 months) (2) . In addition, all children aged 6 months to <9 years who have not been previously vaccinated at any time should receive 2 doses of influenza vaccine (2) . Vaccine should be offered throughout the influenza season, even after influenza activity has been documented in the community.
Influenza surveillance reports for the United States are posted online weekly during October-May and are available at http://www.cdc.gov/flu/weekly/fluactivity.htm. Additional information regarding influenza viruses, influenza surveillance, the influenza vaccine, and avian influenza is available at http:// www.cdc.gov/flu. Additional information regarding classification of deaths according to intent and mechanism is available at http://www.cdc.gov/nchs/data/nvsr/nvsr54/ nvsr54_10.pdf.
During 1979-2004, the three leading causes of injury death in the United States were motor-vehicle traffic, firearm, and poisoning (including drug overdose). In 2004, for the first time since 1968, when such data first became available, the number of reported poisoning deaths (30,308) and the age-adjusted poisoning death rate (10.3 per 1000,000 population) exceeded the number of firearm deaths (29,569) and the firearm death rate (10.0), respectively. During 1999-2004, the poisoning death rate increased 45%, whereas the firearm death rate declined 3%; during the same period, no change occurred in the rate (14.7) for motor-vehicle traffic deaths.
SOURCE:
Mortality data from the National Vital Statistics Systems. Available at http://www.cdc.gov/nchs/ deaths.htm. † Calculated by summing the incidence counts for the current week, the two weeks preceding the current week, and the two weeks following the current week, for a total of 5 preceding years. Additional information is available at http://www.cdc.gov/epo/dphsi/phs/files/5yearweeklyaverage.pdf. § Not notifiable in all states. ¶ Includes both neuroinvasive and non-neuroinvasive. Updated weekly from reports to the Division of Vector-Borne Infectious Diseases, National Center for Zoonotic, VectorBorne, and Enteric Diseases (proposed) (ArboNET Surveillance). ** Data for H. influenzae (all ages, all serotypes) are available in Table II . † † Updated monthly from reports to the Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (proposed). Implementation of HIV reporting influences the number of cases reported. Pediatric HIV data will not be updated monthly for the remainder of this year due to upgrading of the national HIV/ AIDS surveillance data management system. Data for HIV/AIDS are available in Table IV quarterly. § § Updated weekly from reports to the Influenza Division, National Center for Immunization and Respiratory Diseases (proposed). ¶ ¶ No measles cases were reported for the current week. *** Data for meningococcal disease (all serogroups and unknown serogroups) are available in Table II . † † † Updated weekly from reports to the Division of Viral and Rickettsial Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases (proposed). American Samoa American Samoa American Samoa 
